Description

4-o-[(N,n-Diisobutylcarbamoyl)Methyl]Rifamycin is a chemically modified derivative of the potent ansamycin antibiotic, rifamycin SV, designed to enhance its pharmacological profile and stability. This semi-synthetic compound is critical for pharmaceutical research and development, particularly in the creation of advanced antibacterial agents targeting resistant strains. It serves as a key intermediate for medicinal chemists and manufacturers in the pharmaceutical and biotechnology sectors focused on novel anti-infective therapies.

Application

• Pharmaceutical Intermediate: Primary use as a crucial building block in the synthesis of next-generation rifamycin-based antibiotics.
• Antibacterial Research: Serves as a reference standard and active material in R&D for studying structure-activity relationships against Gram-positive bacteria and Mycobacterium tuberculosis.
• API Synthesis: Used in the production pathway for Active Pharmaceutical Ingredients (APIs) in anti-tuberculosis and anti-staphylococcal medications.
• Medicinal Chemistry: A valuable substrate for further chemical modifications to improve solubility, bioavailability, and reduce bacterial resistance.
• Biochemical Studies: Employed in microbiological and enzymatic assays to investigate bacterial RNA polymerase inhibition.

Basic Information

Product Name	4-o-[(N,n-Diisobutylcarbamoyl)Methyl]Rifamycin
CAS No.	16784-05-7
Molecular Formula	C46H64N2O13
Molecular Weight	853.01 g/mol
Synonyms	4-O-[(N,N-Diisobutylcarbamoyl)methyl]rifamycin; Rifamycin Derivative 4-O-carbamoylmethyl; 3-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin SV; 4-Deoxy-3,4-[2-(diisobutylamino)-2-oxoethylidene]rifamycin; Rifamycin 4-O-(N,N-diisobutylcarbamoylmethyl) ether; Antibiotic XZ-450; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-21-Acetoxy-6,9,17,19-tetrahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1-oxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-5-yl 2-(diisobutylamino)-2-oxoacetate
EINECS	Contact for details

Quality Control

Our 4-o-[(N,n-Diisobutylcarbamoyl)Methyl]Rifamycin is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation, to ensure it meets the high standards required for pharmaceutical R&D and synthesis. A comprehensive Certificate of Analysis (COA) detailing purity, related substances, and residual solvents is provided with every shipment to guarantee traceability and compliance.

Storage

Preserve in a tightly closed container, protected from light. Store in a freezer at -20°C or below under an inert atmosphere (e.g., nitrogen or argon) to prevent oxidation and degradation. Allow the sealed container to reach room temperature before opening to minimize moisture condensation. Keep away from strong oxidizing agents.

Specification

Item	Specification
Appearance	Reddish-brown to orange amorphous powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 95.0%
Related Substances (HPLC)	Total impurities ≤ 5.0%
Water Content (KF)	≤ 2.0%
Residual Solvents (GC)	Meets ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.